|Bid||33.85 x 2000|
|Ask||33.87 x 1700|
|Day's Range||33.63 - 34.05|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||25.30|
|Dividend & Yield||1.90 (5.61%)|
|1y Target Est||34.87|
ertex Pharmaceuticals’ Orkambi also secured U.S. Food and Drug Administration’s (or FDA) approval for CF patients in the age group of six to 11 years in September 2016.
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
GlaxoSmithKline (Other OTC: GLAXF - news) 's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.